Nuvation Bio presented its growth strategy at the Citigroup Biopharma Back to School Summit 2026 on September 9, centering on three pillars: its approved ROS1 lung-cancer drug ibtrozi, the investigational glioma candidate safusidenib, and a self-built dual-directed conjugate (DDC) platform.
The company reported a cash balance of approximately $700 million and a market capitalization of $2.31 billion. Trailing twelve-month revenue reached $169.9 million, reflecting more than 1,000% growth, with a gross profit margin of 88%. Shares have returned 97% over the past year and carry a beta of 1.53.
Ibtrozi (taletrectinib) received FDA approval roughly 13 months before the summit and has become the leading ROS1 tyrosine kinase inhibitor on the market. About 85% of treated patients are in the first-line setting. Clinical data spanning more than four years show a 90% response rate and a median duration of response exceeding 15 months. Among 337 patients, only one discontinued therapy due to an adverse event; liver function test elevation was the most common side effect and was described as clinically asymptomatic.
Internal electronic medical record analysis of 39,000 records found that ROS1 alterations affect approximately 2.1% of non-small cell lung cancer patients, translating to an annual U.S. pool of roughly 3,000 new patients. At an annual drug price of about $350,000, the theoretical peak market for newly diagnosed patients is approximately $1 billion annually. When extended response durations are factored in, that figure could scale to $4 billion–$5 billion, potentially exceeding $5 billion with broader RNA-based testing. Testing rates approach 100% at academic centers but remain at 30%–40% in community settings. Japan and China exhibit high testing rates alongside relatively low chemo-immunotherapy usage. Nuvation Bio partnered with Eisai to commercialize ibtrozi in Europe.
On the glioma front, three-year data for safusidenib showed a 52% response rate, a 79% non-progression rate, and a 6% complete response rate in high-grade glioma — including one glioblastoma complete response lasting 3.5 years. Drug discontinuation due to related adverse events was 7%.
In head-to-head comparisons with Sanofi and Ipsen's vorasidenib (Survive), safusidenib posted a 44% response rate in low-grade glioma versus 11% for vorasidenib, and 17% in high-grade glioma versus 0%. One-year and two-year progression rates were 4% and 12% for safusidenib, compared with 23% and 41% for vorasidenib. Vorasidenib is priced at approximately $40,000 per month — roughly 30% higher than ibtrozi — and had reached about a $2 billion annual run rate after nearly 18 months on the market, treating over 5,500 patients with an estimated 25% having progressed.
Nuvation Bio's main pivotal maintenance study, SYGMA, is tracking progression-free survival with a readout targeted for 2029. Additional exploratory pathways include a grade 3 oligodendroglioma study, a post-vorasidenib failure study, tumor growth-rate analysis, and an ex-U.S. low-grade glioma study.
The DDC platform — which fuses small molecules and small-molecule warheads instead of large antibodies to improve tumor penetration and intracellular access — has seen investment likely exceeding $100 million. Candidate NUV-1511 completed a first-in-human study, and molecules are being redesigned based on initial clinical learnings, with an update expected later in 2024.
CEO David Hung and CFO Philippe Sauvage led the presentation.
